Stefan Grant, MD
Hematology & Oncology · New Orleans, LANPI 1407979032
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,846 of the $9,480 with a category attached, or 93.3%. Foundation Medicine, Inc. accounts for 91.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $8,646 and has fallen 96.1% since, to $340 in 2025.
Across 26 payments — averaging $364.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$9K
- Novocure GmbH$200
- Daiichi Sankyo Inc.$76
- Genentech USA, Inc.$65
- Merck$59
- AVEO Pharmaceuticals, Inc.$52
- plus $382 from 13 others
Across 48 payments — averaging $5233.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$76K
- Pfizer$60K
- Bristol Myers Squibb$49K
- Genentech, Inc.$36K
- E.r. Squibb & Sons, L.L.C.$14K
- Merck$13K
- plus $4K from 1 others
What the payments were for
- Speaking & faculty fees$8,84693%
- Food & beverage$5576%
- Education$771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 1 | $8,646 |
| Novocure GmbH | 1 | $200 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Genentech USA, Inc. | 1 | $65 |
| Merck | 2 | $59 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| Novartis | 2 | $51 |
| Array Biopharma Inc | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Servier Pharmaceuticals LLC | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Pharmaessentia USA Corporation | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$8,646
How this compares
$9,480 in reported general payments places this provider in the 65th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.